BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 12912872)

  • 1. Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration.
    Lanzini A; De Tavonatti MG; Panarotto B; Scalia S; Mora A; Benini F; Baisini O; Lanzarotto F
    Gut; 2003 Sep; 52(9):1371-5. PubMed ID: 12912872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA).
    Chazouillères O; Marteau P; Haniche M; Jian R; Poupon R
    Dig Dis Sci; 1996 Dec; 41(12):2417-22. PubMed ID: 9011452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
    Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
    J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis.
    Zuo P; Dobbins RL; O'Connor-Semmes RL; Young MA
    CPT Pharmacometrics Syst Pharmacol; 2016 Aug; 5(8):418-26. PubMed ID: 27537780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test.
    Eusufzai S; Ericsson S; Cederlund T; Einarsson K; Angelin B
    Gut; 1991 Sep; 32(9):1044-8. PubMed ID: 1916489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct measurement of first-pass ileal clearance of a bile acid in humans.
    Galatola G; Jazrawi RP; Bridges C; Joseph AE; Northfield TC
    Gastroenterology; 1991 Apr; 100(4):1100-5. PubMed ID: 2001808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
    Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
    Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical application of a selenium (75Se)-labelled bile acid for the investigation of terminal ileal function.
    Nyhlin H; Brydon G; Danielsson A; Westman S
    Hepatogastroenterology; 1984 Aug; 31(4):187-91. PubMed ID: 6479839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.
    Van Hoogstraten HJ; De Smet MB; Renooij W; Breed JG; Engels LG; Den Ouden-Muller JW; Rijk MC; Smit AM; Zwertbroek R; Hop WC; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Aliment Pharmacol Ther; 1998 Oct; 12(10):965-71. PubMed ID: 9798800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis.
    Verma A; Maxwell JD; Ang L; Davis T; Hodges S; Northfield TC; Zaidi M; Pazianas M
    Osteoporos Int; 2002 Aug; 13(8):677-82. PubMed ID: 12181628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
    Rudolph G; Kloeters-Plachky P; Sauer P; Stiehl A
    Eur J Clin Invest; 2002 Aug; 32(8):575-80. PubMed ID: 12190957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of cholestasis on absorption of ursodeoxycholic acid.
    Sauer P; Benz C; Rudolph G; Klöters-Plachky P; Stremmel W; Stiehl A
    Dig Dis Sci; 1999 Apr; 44(4):817-22. PubMed ID: 10219843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
    Verma A; Jazrawi RP; Ahmed HA; Davis T; Bland JM; Benson M; Orchard RT; Theodossi A; Maxwell JD; Northfield TC
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1069-76. PubMed ID: 10524634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.
    Combes B; Carithers RL; Maddrey WC; Munoz S; Garcia-Tsao G; Bonner GF; Boyer JL; Luketic VA; Shiffman ML; Peters MG; White H; Zetterman RK; Risser R; Rossi SS; Hofmann AF
    Hepatology; 1999 Jun; 29(6):1649-54. PubMed ID: 10347103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.
    Eriksson LS; Olsson R; Glauman H; Prytz H; Befrits R; Rydén BO; Einarsson K; Lindgren S; Wallerstedt S; Wedén M
    Scand J Gastroenterol; 1997 Feb; 32(2):179-86. PubMed ID: 9051880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile acid malabsorption investigated by selenium-75-homocholic acid taurine ((75)SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea.
    Borghede MK; Schlütter JM; Agnholt JS; Christensen LA; Gormsen LC; Dahlerup JF
    Eur J Intern Med; 2011 Dec; 22(6):e137-40. PubMed ID: 22075299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man.
    Marteau P; Chazouilléres O; Myara A; Jian R; Rambaud JC; Poupon R
    Hepatology; 1990 Nov; 12(5):1206-8. PubMed ID: 2227819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
    Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
    BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.